|
Well, I am one of those guys who, believing the risk to be too high with the underlying, went for the out of the money calls to participate in the upside. I totally concur with everyone who cites the provigil part of the pipeline as one with tremendous potential. If it could be another ritalin, look out. I think the market is saying, great, the narcoleptic market is not that large. But if it is used as a ritalin-type stimulant, think about the market potential. I am still shying away from the underlying and looking for the options again, but until the timing can be cleared up, I am on the sidelines. Is May 11 still intact? Do we have a confirmation on that fact? I think it is a critical question for the company/IR to answer, but I don't think they even know. I still believe that the panel would have to have done the dirty work. Good luck guys and cheers to informed posters like yourselves. |
